Jazz Pharmaceuticals (JAZZ) Total Liabilities (2010 - 2026)

Jazz Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• In Q1 2026, Total Liabilities changed 0.44% year-over-year to $7.3 billion; the TTM figure through Mar 2026 stood at $7.3 billion (changed 0.44% YoY), while the FY2025 annual figure was $7.3 billion, down 7.3% from the prior year.
• Total Liabilities was $7.3 billion for Q1 2026 at Jazz Pharmaceuticals, roughly flat from $7.3 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $8.2 billion in Q1 2022 to a low of $7.2 billion in Q2 2025.
• Historically, Total Liabilities has averaged $7.7 billion across 5 years, with a median of $7.7 billion in 2023.
• Biggest YoY gain for Total Liabilities was 175.8% in 2022; the steepest drop was 11.92% in 2022.
• A 5-year view of Total Liabilities shows it stood at $7.7 billion in 2022, then decreased by 1.2% to $7.7 billion in 2023, then rose by 3.42% to $7.9 billion in 2024, then retreated by 7.3% to $7.3 billion in 2025, then dropped by 0.18% to $7.3 billion in 2026.
• The last three Total Liabilities figures came in at $7.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $7.4 billion (Q3 2025), per Business Quant data.